CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO Participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run Following European Clinical Trial Site Activations

  • CNS Pharmaceuticals CEO John Climaco participated in 5K run on November 5, to show support for brain tumor patients worldwide and help raise funds for research
  • The company recently announced European clinical trial site activations for its potentially pivotal global trial evaluating Berubicin for the treatment of recurring glioblastoma multiforme
  • The pivotal trial will study Berubicin’s results compared to the current study of care, Lomustine
  • Global brain tumor treatment market was valued at $2,946 million in 2022 and is expected to grow to $5,904 million by 2032

Brain and other central nervous system cancers (“CNS”) represent 1.3% of all new cancer cases in the United States. In 2022, Cancer.gov estimates that there will be 25,050 new cases of brain and CNS cancers, with 18,280 patients dying from the disease (https://ibn.fm/JG0QS). To help raise awareness of these statistics, CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, announced that CEO John Climaco participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run on November 5, 2022, in Los Angeles, California.

“The unmet need in brain tumor treatment is immense and knows no geographic borders. As CEO of CNS, I have come to know many brain tumor patients personally, and the optimism and strength with which they have all faced this terrible diagnosis is a continuing source of inspiration to me,” Climaco commenting, underlining that supporting these patients, their journey, and challenges is both a priority and the core purpose of his company (https://ibn.fm/98YAN). “Across the globe, there is an urgent need for safe and effective GBM treatment options, and I am proud to participate in the BT5K to support the mission of the ABTA, to help bring hope to patients and families, and to raise much-needed funds for research.”

The Breakthrough for Brain Tumors(R) 5K Run took place in Hahamongna Watershed Park in Pasadena and will help The American Brain Tumor Association to create and provide patient and caregiver-focused programs throughout the year. These include patient and family meetings, the annual National Conference, and continuing to explore new programs and relationships in the area. Climaco was the single largest fundraiser for the event by raising nearly $5,000 and also placed 7th in his first-ever 5K race. More information the 5K can be found at https://ibn.fm/rfhM4.

NetworkNewsAudio (“NNA”), which delivers additional visibility, recognition, and brand awareness in the investment community via distribution to thousands of syndications, recently featured CNS Pharmaceuticals’ recent announcement highlighting the activation of European clinical trial sites for its potentially pivotal global trial evaluating Berubicin for the treatment of recurring glioblastoma multiforme (“GBM”). GBM is one of the most aggressive types of brain cancer, and Berubicin is the first anthracycline to appear to cross the blood-brain barrier. The results from this pivotal trial will compare Berubicin to a current standard of care, Lomustine, with a 2 to 1 randomization of patients to receive either Berubicin or Lomustine (https://ibn.fm/7ZWYY). 

The global brain tumor treatment market was valued at $2,946 million in 2022. This value is expected to grow at a CAGR of 7.2% over the forecast period, resulting in a valuation of $5,904 million by 2032. Medication advancements and the efficiency of treatments are expected to be a driving factor for growth within the industry – with more pharmaceutical R&D spending also expected (https://ibn.fm/ZecMG).

CNS has been granted FDA Fast Track Designation for Berubicin, enabling more frequent interactions with the FDA for guidance on expediting the development and review process. The company has also received an Orphan Drug Designation, which may provide seven years of marketing exclusivity upon approval of an NDA.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems Los Angeles, California www.TinyGems.net 310.299.1717 Office Editor@TinyGems.net

TinyGems is part of the InvestorBrandNetwork

Archives

Select A Month

Contact us: (310) 299-1717